The Austria-based biotech company is working on the vaccine in conjunction with the Institut Pasteur in France. The research institute holds extensive rights to the new vaccine through a licensing deal with the company.
The Zika vaccine is based on previous technology the biotech used to make a measles vaccine.
Erich Tauber, MD, CEO of Themis Bioscience, says the vaccine’s development will benefit from the technology’s proven track record for immunizing against measles.
More articles on supply chain:
Medtronic invests $20M in Mazor Robotics
FDA panel endorses Amgen’s biosimilar version of Humira
GE stakes claim on cell therapy market with Biosafe acquisition
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
